Tech2 News employeeAugust 2, 2021 8:07:43 AM
Following the announcement of the results of the Phase 2 human trial of the COVID-19 vaccine Covaxin in India, Barrat Biotech is now starting testing intranasal vaccines in different parts of the country. According to the company, phase I studies are being carried out in Patna, Chennai, Hyderabad and Nagpur; called intrasal vaccine BBV154, Tested to prevent COVID-19 infection. If a vaccinated person becomes infected, the vaccine is also said to prevent the progression of COVID-19 disease. Time will tell whether this vaccine will be successful with Covaxin, another COVID-19 vaccine from Bharat Biotech. Covaxin was found to be 80.4% effective in preventing COVID-19 disease.
Here’s what you need to know about this new form of vaccine when starting the study:
Barrat Biotech Nasal Vaccine
Hyderabad-based Bharat Biotech is working on India’s first intranasal vaccine against COVID-19 in partnership with Precision Virologics, a startup cultivated at Washington University in St. Louis, USA. The vaccine was developed by University of Washington professors David Curiel, a cancer biologist, and Michael Diamond, a viral immunologist. St. Louis mail delivery report..
The phase I study was conducted by a US startup at a university hospital to evaluate vaccines and treatments in St. Louis. Once this is complete, Bharat Biotech will also conduct testing in India. If both tests give good results, Bharat Biotech Then the vaccine is made. I bought the right to distribute Vaccines for all global markets except the US, Japan and Europe.
Nasal administration has several advantages as it requires a much smaller single dose than an injection.
More information on the techniques used and data from animal experiments were published in the journal cell, In an editorial with nature..
The results show that BBV154 provided “an unprecedented level of protection in mouse studies”.
BBV154 Intranasal Vaccine
The most common way to spread COVID-19 is by air. Either large droplets from close contact or small droplets called aerosols. The SARS-CoV-2 virus usually enters the body through the nose. Intranasal vaccines are not injected into the skin, but are given nasally. With this vaccination, the vaccine targets the virus present in the nasal mucus, which is where the maximum load of the SARS-CoV-2 virus is also likely to be present.
Nasal vaccines can be given as a spray, needle, or syringe without nasal drops Indian era When the vaccine is reported to be given through nasal drops, it blocks the virus locally (nasally) and stimulates the immune system to make proteins in the blood known as antibodies that can fight infectious microbes.
Barrat Biotech’s Nasal Vaccine is an adenoviral vector vaccine originally made from a weakened version of the chimpanzee-supplied cold virus. It has been modified to target like a coronavirus. Covaxin is being administered to Indians as part of the world’s largest phased vaccination campaign, in addition to the Covishield vaccine developed by AstraZeneca and Oxford University and manufactured by the Serum Institute of India.
Naturally reportIn animal studies, mice with the single-dose nasal vaccine were “completely protected from SARS-CoV-2 with few signs of virus in their upper or lower respiratory tract”.
In contrast, vaccinated mice were only partially protected.
Nasal vaccines have many advantages over injections in that they require a much smaller single dose than injections. St. Louise Post Report. Nasal vaccines are “easy to administer” because they involve a spray and minimal training. It’s beneficial for both children and adults who may be afraid of needles.
Clinical studies in India
India’s Leading Medicines Agency, the Drugs Controller General of India (CDSCO), Authorized Phase I and Phase II studies of nasal vaccines that Barrat Biotech planned last month. The CDSCO Subject Expert Committee (SEC) recommended that companies generate safety and immunogenicity data from a Phase I study with 75 volunteers. However, higher numbers are mentioned in other reports – for example 150–175 – Phase 1 research volunteers.
“A candidate for a nasal vaccine has been identified. It is now being considered in Phase 1 and Phase 2 trials. If it works, it could be a game changer, ”said Niti Aayog, a member of Niti Aayog. ) VK Paul says. Said India Express.
Forty-two days after administration of the nasal spray, an interim analysis of the results is performed. To participate in the vaccine study, volunteers must be healthy adults who are free of comorbidities and are not infected with COVID-19.
According to sources, trials have already started in hospitals in Hyderabad, Nagpur, Patna and Chennai. Hindu business branch.
Four countries around the world are working on different intranasal vaccines.
Other nasal vaccines under development
Three other countries around the world are also testing intranasal vaccines. Together with India, US companies Altimmun We’re developing a nasal spray called AdCOVID. The vaccine is said to be particularly effective in preventing COVID-19 infection in children. They started the study with a group of 180 volunteers between the ages of 18 and 55.
In England Codagenix The nasal vaccine COVI-VAC has entered phase 1 clinical trials and is being tested by 48 volunteers. The vaccine recognized the entire virus, not just the spike protein. This vaccine is being developed in collaboration with the Serum Institute of India.
China is not left behind and is also working on an intranasal vaccine. Beijing Wang Thai Organic Pharmacy Enterprise works with Xiamen University and the University of Hong Kong. Phase I trials with this vaccine were approved and started in November 2020. Intranasal sprays are made up of attenuated influenza viruses such as H1N1, H3N2 and B that carry the gene segment of the COVID-19 peplomer. Phase 1 consisted of 100 volunteers and should last a year.
publisher’s Note: This article was first published on March 12, 2021 when Bharat Biotech began testing intranasal vaccines nationwide. On August 1, a panel of experts from the Central Pharmaceutical Authority of India recommended that Bharat Biotech approve a study on the compatibility of Covacin with the nasal vaccine candidate currently under study, BBV154.
Everything we know so far about BBV154 – technology news, Firstpost source link Everything we know so far about BBV154 – technology news, firstpost
